Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:PARD
CUSIPN/A
Phone206-286-2501
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares1,500,000
Poniard Pharmaceuticals (OTCMKTS:PARD) Frequently Asked Questions
What is Poniard Pharmaceuticals' stock symbol?
Poniard Pharmaceuticals trades on the OTCMKTS under the ticker symbol "PARD."
Who are some of Poniard Pharmaceuticals' key competitors?
Who are Poniard Pharmaceuticals' key executives?
Poniard Pharmaceuticals' management team includes the folowing people:
- Ronald A. Martell, Chairman of the Board (Age 54)
- Robert S. Basso, Independent Director (Age 67)
- Frederick B. Craves Ph.D., Independent Director (Age 70)
- Carl S. Goldfischer M.D., Independent Director (Age 58)
- Robert M. Littauer, Independent Director (Age 56)
- David R. Stevens Ph.D., Independent Director (Age 67)
Has Poniard Pharmaceuticals been receiving favorable news coverage?
Media coverage about PARD stock has trended very positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Poniard Pharmaceuticals earned a coverage optimism score of 0.70 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 43.66 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Poniard Pharmaceuticals?
Shares of PARD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Poniard Pharmaceuticals' stock price today?
One share of PARD stock can currently be purchased for approximately $0.0440.
How big of a company is Poniard Pharmaceuticals?
Poniard Pharmaceuticals has a market capitalization of $70,000.00.
How can I contact Poniard Pharmaceuticals?
Poniard Pharmaceuticals' mailing address is 750 BATTERY STREET SUITE 330, SAN FRANCISCO CA, 98119-4114. The biopharmaceutical company can be reached via phone at 206-286-2501 or via email at [email protected]
MarketBeat Community Rating for Poniard Pharmaceuticals (PARD)
MarketBeat's community ratings are surveys of what our community members think about Poniard Pharmaceuticals and other stocks. Vote "Outperform" if you believe PARD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PARD will underperform the S&P 500 over the long term. You may vote once every thirty days.
